Sangamo Therapeutics (NASDAQ: SGMO) and Radius Health (NASDAQ:RDUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Earnings and Valuation

This table compares Sangamo Therapeutics and Radius Health’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Sangamo Therapeutics $23.42 million 53.55 -$57.47 million ($0.81) -18.52
Radius Health $980,000.00 1,711.31 -$225.19 million ($5.19) -7.43

Sangamo Therapeutics has higher revenue and earnings than Radius Health. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Sangamo Therapeutics and Radius Health, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sangamo Therapeutics 0 2 3 0 2.60
Radius Health 0 2 5 0 2.71

Sangamo Therapeutics presently has a consensus target price of $15.00, suggesting a potential upside of 0.00%. Radius Health has a consensus target price of $53.60, suggesting a potential upside of 39.04%. Given Radius Health’s stronger consensus rating and higher probable upside, analysts plainly believe Radius Health is more favorable than Sangamo Therapeutics.


This table compares Sangamo Therapeutics and Radius Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sangamo Therapeutics -246.39% -38.49% -30.67%
Radius Health N/A -79.46% -71.59%

Institutional & Insider Ownership

63.4% of Sangamo Therapeutics shares are owned by institutional investors. 5.5% of Sangamo Therapeutics shares are owned by insiders. Comparatively, 15.0% of Radius Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Sangamo Therapeutics has a beta of 3.14, meaning that its stock price is 214% more volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.


Sangamo Therapeutics beats Radius Health on 7 of the 13 factors compared between the two stocks.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has clinical and preclinical programs in development and partnered certain programs with biopharmaceutical companies to expedite clinical and commercial development. The focus for its Company is the development of human therapeutics. The Company’s product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. The Company has initiated a Phase I/II clinical trial evaluating its zinc finger nuclease (ZFN) in vivo genome editing approach for the treatment of hemophilia B. In the development of its ZFP technology platform, it is focusing its resources on product development for therapeutic use in humans and on its non-therapeutic applications.

About Radius Health

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Company‚Äôs clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Its RAD140 is a non-steroidal, selective androgen receptor modulator (SARM). RAD140 is under development for potential use in hormone receptor positive breast cancer.

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.